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SUMMARY
The lymphatic system has three primary roles: transporting lipids, trans-
porting immune cells, and maintaining fluid balance. Each one of these roles are
influenced by the presence of flow. Inflammation increases lymph flow, lipid uptake
is enhanced by flow, cancer cell migration increases in the presence of flow, and lym-
phatic permeability and lymphatic contractility respond to changes in flow. Flow
is very important to lymphatic function, and yet, there are no in vitro models that
incorporate both luminal (flow along cell lumen) and transmural (flow through cell
lumina) flow for lymphatics.
To address this need, a microfluidic device has been developed that can incorporate
both of these types of flow. This is achieved by driving flow through a channel
which creates a pressure gradient that drives fluid through a porous membrane into
an adjacent channel. Following several design iterations, the device can be easily
fabricated, imaged, and cells can grow and survive in it.
Permeability experiments have been performed in static and flow, 0.175 mL/min
(0.5 dyne/cm2), cases. The effective permeability of dextran in the static and flow
cases was calculated to be 0.0083 µm/s and 2.05 µm/s respectively. While the effective
permeability of bodipy in the static and flow cases was calculated to be 0.0053 µm/s
and 2.57 µm/s respectively. The static values are similar to values obtained in a
transwell study by Dixon et al. As mentioned, lipid uptake is increased in the presence
of flow and these numbers suggest the same.
In addition to permeability studies, experiments were performed with cancer cells
suspended in a collagen gel. Two image processing techniques were used to quantify
cancer cell migration. The first technique was used to calculate the number of cells
xi
present at the beginning of the experiment and the number of cells that were ever
present during the experiment in that particular z slice. The static case yielded a cell
flux of 15 additional cells. While the two flow cases, within interstitial flow range,
had a flux of 24 and 40 cells. This suggests that flow increases migration in cancer
cells and is in agreement with the literature. The second technique was used to show
that the cells in the static and flow cases are similarly motile, but the flow case is
more directed in the z direction towards the membrane.
The future work for this device is quite extensive, but a strong foundation cen-






Lymphatics are responsible for transporting fluids, cells, and lipids [13] and, yet,
very little is known about the molecular mechanisms involved in these tasks. Strides
have been taken to develop tissue-engineered models that can be used to charac-
terize the transport mechanisms involved [13], but these models do not account for
transmural or luminal flow. Lymphatic function is immensely affected by interstitial
flow[13][28][37][46][17], for example flow can act as a signaling cue to lymphatics dur-
ing inflammation [37]. The lymphatics are also involved in cancer cell metastasis and
transmural flow has been shown to act as a tumor cell homing mediator to lymphatics
[52]. There are, however, no current models of lymphatics than can incorporate both
luminal and transmural flow. A model that can better recapitulate the lymphatics
would be an invaluable tool for studying the effects of flow on lymphatic endothelial
cell function.
1.2 Solution and Benefits
A microfluidic device has been developed consisting of two channels that are separated
by a porous membrane. This device is used in two specific disease models: a model
of lymphedema and a model of cancer metastasis via lymphatics. Both luminal and
transmural flow can be produced with this device. Luminal flow can be achieved
by driving flow through a channel and over a cell layer. The act of driving this flow
creates a pressure gradient through the porous membrane which results in transmural
1
flow going through the cell layer. Some benefits to using an in vitro model with three-
dimensional microenvironments over an in vivo model include the use of human cells,
polarization of transport, and separable inputs. In vitro experiments can be high






The lymphatic system is primarily responsible for maintaining fluid balance, trans-
porting immune cells, and absorbing and delivering lipids to the circulatory system
[13]. Without lymphatic function life stops [28]. There are two distinct types of lym-
phatic vessels: initial and collecting. The initial lymphatics are blind-ended tubes
with “button-like” junctions [3]. When pressure gradients are present, these overlap-
ping junctions allow for fluid to be driven into the lymphatics. Whereas, the collecting
lymphatic junctions are more like “zippers” [3]. These junctions have much tighter
interfaces and limit leaking. Overall, the initial lymphatics allow fluid to enter the
lymphatic system and then the collecting lymphatics transport the lymph.
2.1.2 Fluid Homeostasis
In order to maintain normal tissue homeostasis, lymphatic vessels help to return the
fluid or cells back into the circulatory system [65, 3] through the thoracic duct [15].
This process is also important in inflammatory diseases and cancer due to the high
fluid and cell efflux [65, 3] into the tissue spaces that occurs in these conditions.
Both hydrostatic and colloidal osmotic pressure gradients facilitate entry into the
collecting lymphatics [7, 49, 3], due to a disparity between the pressures [28]. Another
important factor to consider is the permeability of the vessel wall which can change,
because of the lymphatic’s dynamic nature [28]. Starling’s Law
Jv = LPS(∆P − σ∆π) (1)
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takes these factors into consideration. Where Jv is the fluid flux across the surface
area S, LP is the hydraulic permeability, ∆P is the hydrostatic pressure, ∆π is the
oncotic pressure, and σ is a non-dimensional coefficient of the effectiveness of the
interface as a semi-permeable membrane [28]. This equation is generally used more
often with collecting lymphatic vessels.
If the oncotic pressure in Starling’s Law is greater than the hydrostatic pressure,
then the flow can reverse in direction. Generally, in initial lymphatics the oncotic
pressure is thought to be zero. Ficks’ First Law
Js = Pd∆CS (2)
is used for initial lymphatics and it states that when a concentration gradient exists
solutes will move in the direction of the gradient [28]. Where Js is the solute fluid
flux, Pd is the permeability, and ∆C is the concentration gradient [28].
2.1.3 Permeability
From equations 1 and 2 we can see that permeability plays a significant role in fluid
homeostasis and permeability is not necessarily a constant value [27]. For example,
depending on the health of the surrounding vessels and what signaling is occurring,
such as, the permeability of the vessel can change over both space and time within a





can be quantified by using optically labeled tracers, but when using these tracers it
is best to think of the calculated permeability as being the effective permeability of
that particular tracer and not of the whole system. This can be useful for studying
transport of certain tracers, because the uptake into the system could vary depending
on the tracer’s composition.
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2.1.4 Immune Cell Trafficking
The lymphatic system is also extremely important in immune surveillance because
the vessels traffic antigen-presenting cells from tissues to lymph nodes [43, 36, 3].
By transporting lymph or fluid to the lymph nodes, the antigen-presenting cells are
provided with a wide sample of peripheral antigens [29, 41]. Where these antigen-
presenting cells can consist of dendritic cells, macrophages, and B cells [29, 41]. This
transport is especially important for maintaining tolerance to self-antigens and for
inducing an adaptive immunity [16, 37].
Immune cells and several types of cancer cells secrete the chemokines CCL19 and
CCL21 [52]. The cancer cells also have the corresponding receptor CCR7 to the
chemokines [52], which, eventually leads to the cancer cells migrating towards the
draining lymphatic vessel and are transported to the lymph nodes [10].
2.1.5 Lipid Transport
Almost all dietary lipids enter the lymphatics and are transported to the circula-
tory system [13]. In the small intestine, non-soluble free fatty acids are reesterfied
into triglycerides by the enterocytes [13]. These triglycerides are then packaged into
soluble chylomicrons that are capable of moving in the bloodstream’s water-based
solution. The chylomicrons are too large, up to 1200 nm, to be taken up by the
surrounding blood capillaries [59] so they are absorbed by lacteals, blind ended lym-
phatic vessels [59, 13]. Interestingly, lacteals can change their morphology during
fasting and non-fasting to adjust to the varying loads [20] and lymph flow changes,
due to altering the interstitial matrix tissue hydration, can affect chylomicron trans-
port, where an increase in flow would result in an increase in chylomicron transport
[60]. Therefore, it is thought that the lymphatic endothelium might actively regulate
dietary lipid uptake [13].
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Recently, several reviews have highlighted a potential link between lymphatic func-
tion and lipid homeostasis [21, 44, 45, 48, 13]. All dietary lipids enter the circulatory
system through the lymphatic system, however, very little is known about the uptake
mechanisms involved with this process [13]. While the regulation of material flux
through the lymphatic system has been studied extensively, the mechanisms involved
and the routes taken have not been as widely explored [3]. This is heavily due to the
difficulty involved with seeing and isolating lymphatic vessels in vivo [28]. Therefore,
an in vitro model that can recapitulate the biophysical environment seen in vivo could
help expand our knowledge.
If these uptake mechanisms were better understood we may be able to take ad-
vantage of these transport routes for drug delivery. Orally delivered drugs are very
desirable when targeting intestinal lymphatics, because first-pass metabolism can be
avoided. This is because substances absorbed by the lymphatics in the gut bypass
the liver and go straight into the circulation [42].
2.1.6 Lymphatic Dysfunction and Disease
There are two particular states of dysfunction that are the predominant motivations
for the device discussed in this thesis: lymphedema and cancer metastasis. These
diseases and how they relate to this project will be further discussed in the following
sections.
2.1.6.1 Lymphedema
Lymphedema results from an imbalance in fluid maintenance and transport due to
lymphatic failure or blockage which leads to an accumulation of interstitial fluid in
a particular limb [40]. This stagnation of fluid leads to hampered immune responses
[3] like impaired immune cell scavenging and increases the likelihood of infection
[40, 37]. There are two types of lymphedema: primary and secondary. Primary
lymphedema is an inherited disease and secondary lymphedema is a result of injury,
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surgery, radiation, or infection. In secondary lymphedema, fluid stagnation causes
lymphatic hyperplasia to occur [47].
2.1.6.2 Cancer Metastasis
Lymphatics act as a route for dissemination of many types of cancer cells [65, 30, 57, 3,
8, 39]. However, the mechanisms involved with metastasis are not fully understood.[52]
While the role of lymphangiogenesis in lymphatic metastasis remains unclear [9, 53,
64, 66], it is suggested that aggressive tumors secrete lymphangiogenic growth factors
in order to induce lymphangiogenesis [23, 34, 54]. The increase of growth factors
would enhance lymphatic metastasis and aid the dissemination of cancer cells.
2.2 Current Tissue-Engineered Models
Two transwell systems inspired the design of the device discussed in this thesis. The
first is centered around studying lipid uptake mechanisms while the second looks at
cancer cell migration.
2.2.1 Transwell Systems
A transwell, as depicted in figures 1, 2, and 3, is a porous membrane attached to
an insert placed inside a chamber. The membrane acts as a substance for cells to
adhere to and provides a permeable barrier that is useful for distinguishing the effects
to the apical and basal transport across the cells. One of the biggest advantages to
transwells are the ability to isolate the response from a single cell type while still
producing concentration gradients basally or apically. This is not possible with in
vivo systems [47, 13]. Such 3D tissue-engineered models are capable of recapitulating
crucial aspects of in vivo models while providing the ability to use human cells. The
use of transwell systems has lead to major contributions in lymphatic research as well
as several different systems [18, 24, 25, 52, 13].
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2.2.2 Transwell System for Studying Lipid Transport
As mentioned in the Lipid Transport section, lipid uptake mechanisms are not fully
understood. So a tissue-engineered model of the lacteal, intestinal initial lymphatics,
has been developed to study the uptake mechanisms of lipids into the lymphatic
system. This model uses lymphatic endothelial cells (LEC) and an enterocyte cell
layer,differentiated Caco-2 (human colon carcinoma) cells, to mimic the enterocyte
and lacteal interface [13]. Figure 1 shows a basic schematic of the two cell layers
separated by a porous membrane in a transwell system.
Figure 1: Schematic of Cell Layers in Transwell System
This model has been used to study lymphatic function in lipid trafficking [13].
It is especially useful for determining the overall affects of varying lipid content,
lymphatic permeability, and transport routes [13]. Fluorescently labeled dextran and
bodipy were used to quantify permeability across the membrane of the transwell
with LECs, Caco-2’s, and both cell types present. Dextran is a standard diffusive
imagable molecule used to characterize concentration gradients and bodipy is a 16
carbon chain fatty acid used to quantify lipid uptake. In this transwell system, the
effective permeability was measured to be around Peff=.005 µm/s for bodipy and
Peff=0.065 µm/s for 3 kDa dextran [13].
8
The model also has the benefit of being able to separate the two cell layers to test
the response of one cell type to different stimuli. For instance, the secretions from a
transwell with only Caco-2 cells were collected and then introduced to a transwell with
only LECs. This can be helpful in potentially decoupling responses from different
cell types to establish the individual roles of each. This tissue-engineered model
establishes a strong foundation for studying the uptake mechanisms of lymphatic
vessels.
2.2.3 Cancer Metastasis
Lymphatics play a significant role in cancer cell dissemination [52]. Unfortunately, the
mechanisms involved with this process are not fully understood. So a transwell based
model was used with cancer cells to show migration to lymphatics. In this model a
collagen gel with cancer cells suspended in it was used to create a three-dimensional
interface with LECs on the other side of the porous membrane [52]. Where the
collagen gel acts like the interstitial space that the cancer cells migrate through to
get to the draining lymphatic vessels. Refer to figure 2 for a detailed schematic.
Figure 2: Schematic of LEC Layer and Cancer Gel in Transwell System
Shields et al. found an increase in cancer cell migration when transmural flow, 0.1
to 0.8 µm/s, was present, see figure 3 [52], which was in the range of interstitial flow
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in vivo. The cancer cells secrete CCL19 and CCL21 and also have the receptor CCR7
present for these ligands. When flow is present a concentration gradient of CCl19/21
forms around the cells, see figure 4, which serves to direct their migration [52]. This
response is heightened in the presence of other cells that also have CCR7 signaling
[52]. CCR7 is also present in lymph node metastasis with breast cancer[6], melanoma
[56, 63], colorectal [19], esophageal squamous cell [11], prostate [26], head and neck
[62], non-small lung [55], and gastric cancers [35, 52]. This model helped show the
importance of flow and its potential role in tumor cell homing to lymphatics, because
interstitial flow is always directed towards the nearest draining lymphatic.
Figure 3: Schematic of LEC Layer and Cancer Gel in Transwell System with Trans-
mural Flow
Figure 4: Concentration Gradient of CCL19/21 Due to Presence of Flow
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2.3 Importance of Flow
Interstitial flow, 0.1 to 1 µm/s [37], has been shown to have profound affects on
lymphatic function [13, 28, 37, 46, 17]. We know that both diffusion and convection
play a role in solute movement[28]. It is also important to recognize that lymphatic
exchange is dynamic and is subject to acute regulation as well as chronic adaptation
depending on the stimulus [28], such as inflammation or fasting/feeding states. To
further state the dynamic nature of lymphatics, the actions taken by the lymphatic
capillaries following an injury or during inflammation is determined by the type of
immune response triggered [29]. Furthermore, vasoactive agents can induce gradients
in the tissue space by altering permeability and contractility properties [28].
With rapidly growing tumor cells or during inflammation the vascular permeability
severely increases and this results in an increase in lymph flow [37]. Another indicator
of the importance of flow is how sensitive transport is to changes in pressure [13]. From
Starling’s Law, equation 1, we know that the direction and magnitude of lymph flow
is dependent on the pressure gradient [32, 50, 58, 3]. From these statements we
can see that changes in pressure and permeability affect lymphatic transport in both
magnitude and direction. Changes in either of these properties or both could result
in better fluid reabsorption across the lymphatic endothelium [28].
During inflammation, permeability, interstitial fluid pressure, and lymph flow all
increase [4, 22, 5, 38]. It is likely that the increase in flow, and therefore fluid and
cell transport, acts as an early mediator and signal for inflammation [37].
Transmural flow, see figure 3, was used to observe cancer cell migration [52].
During this study, Shields et al. found that in static conditions LECs induced CCR7
chemotaxis of tumor cells, but in transmural flow without LECs they had an increase
in tumor cell migration and it was still CCR7 dependent [52]. Of the four cell types
they tested, ZR75-1 and MDA cells reacted the strongest to the transmural flow [52].
Low levels of transmural flow have also been shown to increase lymphatic permeability,
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dextran transport, aquaporin-2 expression, and dendritic cell transmigration [37].
At this time, the effects of flow have not been researched as extensively as they
should be [37]. Basic functions cannot be performed without flow present. For exam-
ple, in order for lymphangiogenesis to occur in adult mice, interstitial flow must be
present [46] and in disease states, when interstitial flow is weaker, VEGF is unable to
aid cells as effectively as in a normal state [17]. During times such as inflammation
or fasting and feeding states the lymph flow can drastically change which results in
changes to lymphatic function. Permeability and contractility are directly affected by
flow and so is the transport of fluids and cells as well as immune cell trafficking [37].
Therefore, flow is definitely an important factor in lymphatic function and should be
further explored.
2.4 Variations of Current Tissue-Engineered Models
The following two sections propose ways to incorporate both luminal and transmural
flow into current systems. This allows for a more biophysically accurate environment
as well as continually monitoring optically labeled tracers or cells throughout an
experiment.
2.4.1 Lipid Transport
Figure 5 shows the first model. This model is a modification of the previously men-
tioned lipid uptake transwell system that includes luminal and transmural flow. The
previous model was used to study lipid uptake mechanisms, but could not be used to
study changes in permeability in the presence of luminal flow. However, this model
could be used for permeability studies as well as characterizing the affects of shear
with lipid uptake. This device can also be used for drug screening, lipid uptake, and
lymphedema studies. Lymphedema is known to have leaky vasculature which results
in fluid leaving the collecting lymphatic vessels. The progression of how the leaking
vasculature affects permeability will be the predominate focus of this device at this
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time. Physically relevant shear stresses will be used for this disease model. Dixon et
al. found that shear stress is 0.64 ± 0.14 dyne/cm2 in lymphatics [12].
Figure 5: Flow through porous membrane with luminal flow and transmural flow
present
2.4.2 Cancer Metastasis
A slight modification to this flow system could allow for better cancer cell migration
quantification. Shields et al. was able to do an end time quantification of cancer
cell migration, but this method only results in the number of cancer cells that made
their way to the membrane in the transwell and stayed on the membrane. It does
not specifically count the cells that migrated through the membrane, cells that were
on their way to the membrane, motility of the cells, or overall directionality of the
cells. A live cell system that could image and quantify cell migration throughout the
experiment could account for these additional variables. Figure 6 is a modification
of the previous model to allow for a fluid column that could induce a hydrostatic
pressure gradient that would correspond to transmural flow through the collagen gel
with cancer cells suspended in it.
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Figure 6: Flow through collagen gel with cancer cells suspended in the gel
2.5 Project Requirements
From this literature review there are several obvious gaps in our current understand-
ing of flow and its role with lymphatic transport. Several groups have reported the
significance of flow and its affect on permeability and yet so little has been done
to incorporate flow into in vitro models. If we understood how flow influences per-
meability we may have a better idea of how lymphatics respond to flow in cases of
dysfunction, like lymphedema. Another heavily emphasized lymphatic characteris-
tic is its dynamic nature and yet no models are currently capable of imaging these
dynamic properties in real time.
So for this project, flow channels that support the 3D architecture seen in tran-
swells, induce relevant lymphatic shear stresses, and induces relevant interstitial flow
rates will be designed and tested. This requires the use of porous membranes, flow
channels, and the capability to image real time. The following three specific aims
were established for this device.
Aim 1: Device creates physiological relevant environment under which
cells can be cultured and are viable.
Aim 2: Device allows for quantification of effective permeability.
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Aim 3: Device can be used to quantify cell migration.
The first aim establishes that cell culture can actually be done in this device and
that the cells are viable during experiments. The next aim is to ensure that perme-
ability can be quantified in the channels. This is really important for establishing a
foundation for all future studies involving variations of lipid uptake. The final aim
creates a novel quantification system for measuring cell migration in real time. This
is important for measuring overall motility and flux of migration.
2.5.1 Similar Devices
Recently there have been a couple of flow chambers similar to the device featured in
this thesis. Almost all of them use a porous membrane and support the capability
to induce flow, but each have their limitations and do not satisfy the needs of this
project.
The first device is a lung on a chip, see figure 7. This device has a simple design,
with the membrane made from polydimethylsiloxane (PDMS) [14]. While convenient,
PDMS molds have limitations on how small the features can be so extremely small
pore sizes are very challenging with this technique. For this project we would like to be
able to implement commercially available membranes allowing us to use a wide variety
of pore sizes and making its implementation highly flexible. Another limitation with
this device is the overlapping channels. As it is very challenging distinguish changes
in fluorescent concentration for individual channels when they are overlapping.
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Figure 7: Lung on a chip cross sectional view and top view[1]
The next device is significantly more complex than necessary for this project, see
figure 8. In this device, there is a cell culture side and a flow side that are separated
by a membrane [51]. Flow cannot be actively controlled on the cell side so luminal
flow is not a possibility with this device and cells can only be cultured on the cell
side. This does not allow for a co-culture on both sides of the membrane. One really
interesting aspect to the design is the gradient generator which allows for on-chip
control of the flow through the flow channel [51]. Unfortunately, very large flow rates
cannot be achieved.
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Figure 8: Schematic of flow channels with view of membrane layers[2]
There are a few other devices like these that incorporate membranes and flow, but
most either use the pneumatic air valves to control small amounts of flow or rotor bars
to recirculate fluid. To my knowledge, there isn’t a device that supports cell culture





3.1 Design and Fabrication
Throughout the design of this device, there have been several points of consideration.
First, there were a number of specific design requirements for useful and effective
experimentation. Next, I had to incorporate these necessary factors into a design
that could be easily manufactured and also functional for imaging. This chapter will
focus primarily on the evolution of the device as each one of these areas are explored
and then the methods involved with cell culture and imaging. In this section, the
design requirements will be stated and explained. Followed by adjustments for ease
of manufacturing and then final changes for enhancing imaging.
3.1.1 Design Requirements
As mentioned in the previous chapter, the primary requirement was to be able to
induce both luminal and transmural flow over two separate cell regions that share
a common interface through a porous membrane. We need to be able to induce
interstitial flow, 0.1 to 1 µm/s, through the membrane, induce physically accurate
shear stress values, 0.64 ± 0.14 dyne/cm2 for luminal flow, culture multiple cell types
on either side of a porous membrane, have the option of incorporating cells into a
3D construct such as a collagen gel, and these cells need to be able to signal across
this membrane. We also want the flexibility of pore sizes available with commercially
available polycarbonate membranes. For the two outlined models a 3 µm pore size
will be used for the permeability model and a 8 µm pore size will be used for the
cancer migration model. The larger pore sized membrane will be used for the cancer
migration model so cancer cells can migrate through the membrane.
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Aside from reducing sample size, microfluidic devices also need to be scalable
for high-throughput experimentation. The minimum number of test sections for the
device was set at four channels with the intent to scale up later. This allows for two
channels to be static, control channels and the remaining two channels to have flow.
Finally, we wanted the inlets and outlets to be separable so drug screening could be
performed in the future.
3.1.1.1 Prototype 1
In my first design, I wanted all of the outlet channels to be in the same field of
view for imaging. This constraint required the fluid in each channel to be at the
same time step as the other channels, because all of the channels would be imaged
together and discrepancies due to time would cause unnecessary complications. The
bottom channel consists of 1 mm diameter straight channels that eventually converge
in to smaller channels. See figure 9 for COMSOL (COMSOL, Inc., Burlington, Mas-
sachusetts) models of the bottom and top channels. The top channel behaves in a
similar manner, however, it begins with a dip that crosses over the bottom channel.
This lower section, 1 mm2 area, is where any cell interactions would occur.
Figure 9: Comsol rendering of flow in the bottom (left) and isometric (right) channels
of prototype 1
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Table 1 shows how well this prototype fulfills the design requirements as defined
earlier.
Table 1: Fulfillment of Design Requirements by Prototype 1
Feature Satisfied
Physiological Transmural (0.1 µm/s) and Luminal
(τ=0.5 dyne/cm2) Lymphatic Flow
X
Co-Culture Cells X
3 or 8 µm Porous Membrane X
Four Channels X
Separate Inlets and Outlets
3.1.2 Manufacturing Requirements
I decided the best approach for creating these devices would be PDMS cast in re-
usable molds. I decided to mill out these molds from aluminum, because milling is
significantly easier to do than lithography and this also allows for much larger feature
sizes. I chose aluminum because it is easy to cut and it can withstand the heat from
the PDMS curing process (60◦C).
When machining a part, the end mill diameter and your filet allowances play a
huge role in machining time and quality. A short distance between channels requires
a shorter diameter end mill and smaller diameter end mills are more expensive, less
durable, and have a shorter cutting length. They also take a lot more time to cut out
a small section of material than a larger end mill. Limiting the number of tools used
during the mill job is also desirable, because each tool has to be zeroed to the surface
of the part and if these tools are not precisely zeroed then discrepancies will exist in
the depths cut in the part. Depending on how small the tools are, these discrepancies
could prove to be disastrous. There could also be inconsistencies in the surface finish.
This is especially important in microfluidic devices, because you want as smooth
20
a surface as possible for binding PDMS layers together. The other characteristic
associated with end mills is the filet size. Depending on the design, a large filet could
ruin whatever geometry was in the design. To avoid drastic changes, smaller end mills
can be used, but the same problems previously stated will arise. What I ultimately
determined was less complex designs are much easier to manufacture.
Making the mold is the hardest part of manufacturing for this device, but it is not
the only aspect to fabrication. Once the molds are made they have to be attached to
one another and the porous membrane needs to be placed in between the channels. A
plasma cleaner is used to attach PDMS to PDMS. During the plasma treatment, the
PDMS is temporarily made hydrophilic so it can bond to itself. The plasma treatment
is useful, because it only affects the near surface, there is no organic residue, and it
can work on rough, porous, or uneven surfaces. Once the PDMS is plasma treated the
exposed surfaces must be aligned and connected. Depending on the design, this could
prove to be quite difficult. Unfortunately, the commercial membranes from Millipore
(Millipore, Billerica, Massachusetts) do not attach to PDMS when plasma treated.
Which means placing them between two layers of plasma treated PDMS, chemically
attaching them, or suspending them in the PDMS mold while it is curing are the
best options for incorporation. The first three prototypes discussed in this thesis are
significantly smaller than the half inch membranes, which means if the membranes
were simply placed between two layers of cured PDMS the ridges of the channels
would not adhere to anything and the device would most likely not retain its shape
and fluid would leak between the layers. Chemically attaching the membrane could
also be problematic due to biocompatibility constraints, but has been done by other
groups. Finally, having the membrane suspended in PDMS while it is curing presents
its own problems. For instance, PDMS could soak the membrane and clog the pores.
This is avoidable if the interface region is tightly clamped on the membrane.
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3.1.2.1 Prototype 1 Revisited
Once I had an initial design, I went on to design the molds to be used for casting, see
figure 10. Due to the complex geometry of the top channel, a bridge that locks into
the top mold had to be designed in order to complete the mold, see figure 11.
Figure 10: Molds for bottom (left) and top (right) channels
Figure 11: Bridge for top mold
One major disadvantage to this design is the distance between the outlet channels.
The largest end mill I could use to cut between these channels was 0.009 inches
in diameter. With such a small cutter, I would only be able to cut down 0.0045
inches which would not be deep enough for my channels. Another disadvantage
was interfacing with the tubing. The tubing diameter was 0.95 mm and no tubing
connectors could be found to scale up the tubing size. Seeding cells would be difficult
with this device as well. Finally, incorporating the membrane would require treatment
to ensure adherence, something we wanted to avoid if possible.
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Ultimately, this device was not ideal for manufacturing.
3.1.2.2 Prototype 2
The previous prototype was too difficult to mill out so this prototype was designed
with simpler geometric features. This prototype has separate inlets and outlets along
with collagen access channels to help with seeding cells. These access ports allow
placement of collagen treatment directly over the interface which allows for direct
placement of cell seeding. Figure 12 shows a 3D rendering of this prototype and a
top view.
Figure 12: 3D rendering of actual device (left) and top view (right)
Some problems still exist in this design, like how to incorporate the membrane,
very small end mills have to be used (1/32 inch), and four tools needed to be used,
but overall this prototype was a huge improvement over the last and was feasible for
manufacturing. Figure 13 shows the bottom and top molds. The bottom mold had
to be an inverse of the actual design so that when the two layers were plasma treated
together the overlay would be correct. PDMS was cured in these molds and could
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be attached together with plasma treatment. While this device was an improve-
ment, there were still several problems that needed addressing, such as membrane
incorporation and scaling up the number of test sections, see table 2.
Figure 13: Molds for bottom (left) and top (right) channels
Table 2: Fulfillment of Design Requirements by Prototype 2
Feature Satisfied
Physiological Transmural (0.1 µm/s) and Luminal
(τ=0.5 dyne/cm2) Lymphatic Flow
X
Co-Culture Cells X
3 or 8 µm Porous Membrane X
Four Channels
Separate Inlets and Outlets X
3.1.2.3 Prototype 3
Prototype 3 was further simplified from prototype 2 and the top and bottom channels
became mirror images of one another. This new X shape allows for flow channels and
collagen access channels, see figure 14. The biggest improvement was how the mem-
brane was incorporated. Instead of including the tubing connecting columns in the
mold, both the top and bottom channels were placed on either side of the membrane
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and PDMS was filled in around the membrane. This allows for the membrane to be
suspended between both channels in the same layer of PDMS and actually curing the
membrane in the PDMS. See figure 15 for the molds.
Figure 14: Rendering of actual device
Figure 15: Molds for bottom (left) and top (right) channels
Unfortunately, inserting the top mold into the bottom mold did not provide
enough pressure on the membrane and PDMS would leak and coat the membrane
clogging the pores. To fix this problem, a slight modification was made to the molds.
Both the top and bottom molds were modified to be flush against each other and
screws tightened the two pieces together to provide enough force to keep the PDMS
from leaking into the membrane. An access hole was included in the top mold so
25
PDMS could be filled into the mold. See figure 16. An additional cap mold was made
for the tubing interface holes.
Figure 16: Molds for bottom (left) and top (right) channels
This modification kept the membrane from being covered with PDMS and was
successfully integrated into the device. However, the access hole created a new prob-
lem. The meniscus formed from the hole created an extremely flimsy layer that was
prone to tearing and if too much PDMS was put in the device a large bubble would
form, see figure 17. Either way the tubing cap could not be easily applied to the
device which meant interfacing with the device was still problematic. This device did
satisfy all of the design requirement, see table 3, however interfacing was not trivial
so a final design was made.
Figure 17: Rendering of modified prototype 3
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Table 3: Fulfillment of Design Requirements by Prototype 3
Feature Satisfied
Physiological Transmural (0.1 µm/s) and Luminal
(τ=0.5 dyne/cm2) Lymphatic Flow
X
Co-Culture Cells X
3 or 8 µm Porous Membrane X
Four Channels X
Separate Inlets and Outlets X
3.1.2.4 Prototype 4
Prototype 4 involved a completely new approach. Once I had a working prototype
that could incorporate the membrane, I wanted to focus on interfacing with the device.
I decided to create a stand that would act as a device housing and could exert a
clamping force on the device. With this stand I could integrate PDMS tube holders
that would be aligned by the stand over the channels. Then to provide mechanical
support while maintaing optical clarity, I would clamp a slide over the channels. See
figure 18 for an exploded view of the stand and device and for a clamped view.
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Figure 18: Exploded view of the device (left) and clamped together view (right)
The stand uses two different components, a cap and the middle piece. Both the top
and bottom caps are identical, but when placed face to face they can lock together, see
figure 19 left side, with the use of the middle piece. Another interesting characteristic
to the cap is that both the tubing holders and slide fit into milled holes. This can be
seen clearly in figure 18. The second stand component is the middle piece, figure 19
right side. This piece acts as the connector and clamp. It is slightly thinner than the
membrane PDMS piece and it provides the surface that locks the caps in place. This
locking mechanism allows for the top and bottom caps to be independent from one
another. This allows for independent seeding of cells on either side.
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Figure 19: Cap (left) and middle (right) of stand
For the device, the mold of the channels was made in a similar way as the previous
prototype. Two, flush, mirror image channels are screwed together with a membrane
place between the channels, see figure 20. However, instead of filling the PDMS from
the top or bottom a gap was milled on the side of the mold so PDMS could be injected
from the side. Any discrepancies due to overfilling can be cut off. Figure 21 shows a
rendering of the membrane layer as well as a cross-sectional view of the flow regimes
and cell placement.
Figure 20: Mold for channels in prototype 4
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Figure 21: Cross-sectional view of flow in prototype 4
The individual components in this prototype worked great, however, the interface
between the tube holders and slide was subjected to perpetual leaking. To resolve this
issue, the tube holders were modified to act as a cap to the channels, figure 22 left.
Figure 22 right shows the mold for this component. This solution fixed the leaking
problem, but if too much flow was added the PDMS layers occasionally separated.
This generally happened around 1 mL/min flow rate which corresponds to τw=2.86
dyne/cm2, see equation 4. Table 4 shows how well prototype 4 fulfilled the device
requirements.
Figure 22: PDMS channel cap (left) and mold (right)
For rectangular ducts, equation 4 is used to calculate shear stress τ (Pa) from







Table 4: Fulfillment of Design Requirements by Prototype 4
Feature Satisfied
Physiological Transmural (0.1 µm/s) and Luminal
(τ=0.5 dyne/cm2) Lymphatic Flow
X
Co-Culture Cells X
3 or 8 µm Porous Membrane X
Four Channels X
Separate Inlets and Outlets X
3.1.3 Imaging
Once I had a working device that I could seed cells on and induce flow without leaking,
I needed to be able to image the device.
3.1.3.1 Prototype 4 Modified
I had to modify prototype 4 to enhance its imaging capabilities. The metal caps
were in the way of the lens and the PDMS layers had the potential to separate. So
I modified the stand. Instead of using aluminum, I used acrylic and kept the acrylic
over the viewing area of the device. This acrylic cap layer provides a clamping force
on the PDMS layers to keep them from separating. As an added measure, the PDMS
layers were plasma treated together. This meant that collagen could not be applied
only over the intersection and cells could not be limited to the intersection. To keep
the acrylic surface as clear as possible, the holes for the tube holders and screw holes
were the only areas milled. Therefore, the middle section had to increase in thickness
to account for the PDMS channel cap that was previously embedded in the stand
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cap, see figure 23. Table 5 shows that this final modification satisfies all requirements
for the device as well as the imaging constraints. Finally, figure 24 shows the actual
device and stand with food coloring in the channels.
Figure 23: Exploded view of final device and stand
Table 5: Fulfillment of Design Requirements by Modified Prototype 4
Feature Satisfied
Physiological Transmural (0.1 µm/s) and Luminal
(τ=0.5 dyne/cm2) Lymphatic Flow
X
Co-Culture Cells X
3 or 8 µm Porous Membrane X
Four Channels X
Separate Inlets and Outlets X
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Figure 24: Actual device with dyed channels
After several tests with this device, I found that I would get unwanted aberra-
tions during imaging. The two outside channels achieved better clamping while the
two inside channels appeared fuzzy, see figure 6. Another disadvantage was that the
attached PDMS cover distorts viewing of cells, because of mill lines and dust accu-
mulation. To fix this problem, I went back to using a slide over the viewing area. To
prevent leaks I added a lip to the tube holder that I could plasma treat to the slide,
see figure 25 (left). Figure 25 (right) shows the mold for this modification. After
plasma treating the tube holders to the slide, I applied a thin bead of PDMS to the
intersecting line and I let it cure for an hour at 60◦C. Next, I plasma treated the glass
top and bottom pieces to the membrane piece. Finally, to apply flow I inserted it
into a clamp, see figure 26. The clamp allows for flows as high as 17 mL/min before
the device fails, which corresponds to a 48.57 dyne/cm2. This final modification not
only satisfied all of the goals, but also made the images look cleaner and more crisp,
see figure 6. See table 7 for the complete checklist.
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Figure 25: Assembly of membrane with slides and tubing connectors (left) with tube
holder mold (right)
Figure 26: Final prototype with clamp and dyed channels
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Table 6: Images from final modification of prototype 4. 4 different dextran channels





Table 7: Fulfillment of Design Requirements by Final Prototype 4
Feature Satisfied
Physiological Transmural (0.1 µm/s) and Luminal
(τ=0.5 dyne/cm2) Lymphatic Flow
X
Co-Culture Cells X
3 or 8 µm Porous Membrane X
Four Channels X
Separate Inlets and Outlets X
The final device can support transmural and luminal flow through its channels and
it can withstand significantly higher flow rates than those associated with lymphatics.
Cell culture can be done in this device and its identical channels ensure the ability to
culture cells on either side and allows for co-culture across the membrane. Commer-
cially available polycarbonate membranes can be incorporated into this device. This
device has four channels and the capability to easily scale up the number of available
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channels. Finally it has separate inlets and outlets, which allow for separate testing
conditions across the channels, a feature particularly useful for drug screening. The
final design satisfies all of the design requirements and is easy to manufacture.
3.2 Device Preparation
3.2.1 PDMS
A Dow Corning Sylgard 184 Elastomer Kit (Dow Corning, Midland MI) was used for
PDMS. This kit consists of two parts: base and curing agent. A 10:1 ratio of base
to curing agent was used. This solution would then be mixed with a vortex mixer.
Once mixed the PDMS solution would be poured into the molds and then the molds
would be placed in a vacuum chamber for at least 20 minutes so all of the bubbles
could be removed. After all the bubbles were removed the mold would be placed in
the oven at 60◦C for at least 4 hours.
3.2.2 Plasma Treatment
Once all of the components were cured they were removed from their molds, the
attachment side were taped with clear tape until all of the dust was removed. Then the
PDMS and glass slides were placed on the glass slab in the plasma treater, attachment
side up. Air was evacuated from the plasma treater for 2 minutes and then the plasma
treater was be turned to high and a release valve was opened until a magenta color
appeared in the chamber, after which the components were plasma treated for an
additional two minutes. Afterwards, everything is turned off and air is slowly let
back into the chamber. Then the prepared pieces were aligned and stuck together.
3.3 Cell Culture
3.3.1 Lymphatic Endothelial Cells
An Endothelial Cell Basal Media (EBM) solution is used as media for the LECs
and is supplemented with 20% FBS, 1% Glutamax, 1% penicillin-streptomycin, 25
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µg/mL cyclic-AMP, and 1 mg/mL hydrocortisone acetate. Forty µL of type I rat
tail collagen (Invitrogen, Carlsbad, CA) at a concentration of 50 µg/mL in PBS was
applied to all four top channels for one hour. This surface treatment increases cell
attachment. Passage 8 LECs were grown in a flask until 85% confluent. The media
was removed from the flask and 4 mL of PBS was put into the flask for one minute.
During this time, the flask was gently rocked to ensure the PBS touched the walls of
the flask. The PBS was removed and 3 mL of trypsin was added. After 30 seconds
the flask was placed in a microscope to ensure all the cells had detached. Once all of
the cells detached, 7 mL of EBM was added to the flask. This solution was mixed a
few times and then put into a fresh 15 mL tube and spun down at 4◦C for 5 minutes.
Cells were then resuspended in one mL of EBM solution and then counted with a
hemocytometer. Then the LECs were seeded in the top channel of the device, refer to
figure 21, by pipetting a concentration of 180,000 cell per 60 µL into a tube followed
by pipetting air into the tube for exact placement of the cells in the channel. The
cells were allowed to incubate and attach at 37◦C and 5% CO2 for one hour. Tubing
was connected to the device and the channel was flushed with EBM. This removed
any cells that were not attached to the channel, as well as supplying a larger reservoir
of media to the cells. The device was then left in the incubator for at least three
hours before flow experiments were performed.
3.3.2 Collagen Gel
The collagen gel was prepared on ice using 246 µL of 9.3 mg/mL collagen, 5.7 µL
NaOH 1N, 4.5 µL HEPES, 45 µL PBS 10x, 150 µ L deionized water, and 50 µL of the
ZR75-1 cell suspension in serum-free Dulbecco’s Modified Eagle Medium (DMEM).
The DMEM solution consists of 20% FBS and 1% antibiotic-antimicotic mixture. 40
µL of the collagen gel was pipetted into tubing connected to the four top channels
followed by pipetting air into the tubing for exact placement in the channel. It was
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then allowed to polymerize in the incubator at 37◦C for 15 minutes before performing
flow and static experiments.
3.3.3 Dextran/Bodipy Mix
A mix of 14 mL serum free DMEM, 1 mL (10 mg/mL) fatty-acid free albumin, 15 µL
(5 mg/mL) bodipy, and 15 µL (5 mg/mL) cascade blue dextran were mixed together.
Then this solution was injected into the non-cell side for the permeability studies.
3.3.4 Flow studies
For the lipid transport/permeability study flow was incorporated in two channels onto
the top side, cell side, at a flow rate of 0.175 mL/min, which corresponds to a shear
stress of 0.5 dyne/cm2, see equation 4. This solution consisted of serum-free DMEM
to reduce auto-fluorescence. The previously mentioned dextran/bodipy mix was put
in the non-cell side of this device to act as a source channel, while the serum-free
channels acted as a sink channel for bodipy and dextran.
To produce flow in the cancer cell migration study fluid was filled to the top of the
tubing inlet on one side. This corresponded to a 0.8 µm/s velocity and an interstitial
flow rate of about 0.1 µm/s at the membrane interface. This interstitial value was
calculated using a COMSOL model of the channel/membrane interface, see 39 in the
results section and figures 43 and 44 in the appendix. The subdomains were set so
the top channel was the cancer gel and the bottom was just media. The properties
for the media were set to the dynamic viscosity and density of water at 37◦C. While
the density of the collagen gel was set to 9.3 mg/mL and the dynamic viscosity was
10 cP [33]. For boundary conditions, an inlet was set in the cancer gel channel at at
velocity of 0.8 µm/s and the other three planes (one in the cancer gel and two in the
media channel) were set to free surface pressure outlets. A very fine mesh was used
and a solution was compiled.
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3.4 Cell Staining
The LECs were fixed in 4% PFA at room temperature for 15 minutes. Then the
channels were rinsed with PBS three times before adding DAPI for 15 minutes. The
device was placed in a dark drawer during the staining process. Then the device was
rinsed three times with PBS before phalloidin and staining buffer, PBS with 2% BSA,
(1/100 ratio) was added for an hour. The device was again placed in a dark drawer
during the staining process.
3.5 Image Processing
3.5.1 Permeability
In the permeability studies a 2.5x objective was used to take pictures every five
minutes of each test section. By using this larger objective the entire top view of the
x-shaped device could be seen. This was beneficial, because the concentration in both
the source and sink channels could be measured. To quantify the concentration at any
location a region of interest was drawn in Matlab by using the roipoly function. Once
the region of interest was selected a mask was created and the average intensity of that
region was calculated with the mean2 function. A standard curve of intensity versus
concentration was made by using this mask technique on several known concentration
values. The corresponding intensity to each of these known concentrations was plot.
For the experimental results, the intensity values at each time point were measured
with this mask technique and then interpolated with the interp1 function onto the
standard curve and the corresponding concentration was calculated. Next, the flux
was determined for both the static and flow cases This was done by calculating the
exposed volume over time. Finally, the surface area is known and constant for all
cases at 0.5 mm2. So by using equation 3 effective permeability was calculated for
each case. The code for this can be found in the appendix.
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3.5.2 Migration
Images were taken with a 20x objective every five minutes at a constant depth for
each cross-section in the device. Over the course of three hours migration of cells can
be seen, both side to side and in and out of plane. To quantify this movement two
different image processing techniques were used. The first was to count the number
of cells present at the very beginning and then to do a maximum intensity projection
(MIP) of the entire time course to establish the number of cells that were ever present
in the z slice, thus reporting the total flux in and out of this imaging plaen. To do
this the images were all converted to binary, in the imaging program Crystal Image
(Crystal Image, Athens, GA), and a threshold was applied as well as a composite
wavelet matched filter to reduce noise. Next, the channel was measured to estimate
the number of pixels per length and it was determined that 100 square pixels was
about the area of a cell. A watershed separation technique was used to predict and
separate regions where cells could be overlapping and then a clustering technique was
used to calculate how many regions were at least 100 square pixels. By doing this on
both the start and projection images, the difference in number of cells indicated how
many cells fluxed through the region over the course of the experiment.
The second quantification technique used the binary images and noise reduction
techniques from the previous analysis, but instead performed an image subtraction.
Specifically, each image was subtracted from the preceding image to establish the
displacement of the individual cells during each 5 minute interval and then the average
intensity of the whole region was calculated by using the Matlab function mean2 and




4.1 Aim 1: Cell Viability
Once the device was made several experiments were performed with it. First, I
needed to confirm that cells could be seeded and that they could establish healthy
monolayers. There was a lot of trial and error at first due to optimizing a cell seeding
protocol with the device and finding the right seeding density. I tested the following
densities (45, 90, 135, 180 ×103 cells) and found that 180,000 cells produced the
best results upon visual inspection after three hours of incubation and after one day
of incubation. After a few tries I found that pipetting the collagen mixture, see
the methods section for a more detailed description, through a tube into my device
worked best. I injected the cells in a similar manner. Before pipetting the cells
into the device, I would gently mix the cell solution to ensure the cells were evenly
distributed and would then slowly pipette the solution into the the tube, followed by
slowly pipetting air into the tube to get exact placement of the cell solution in the
channel. I found that a seeding density of 180,000 cells per 60 µL produced evenly
distributed cells throughout my channels. After incubating the cells for three hours I
would also have confluent, healthy monolayers, at which point a cancer gel could be
injected and/or flow experiments could be performed.
After the flow experiments, LECs were fixed and stained with dapi and phalloidin
to visual the nucleus and actin filaments. Note, the cancer cells were stained with a
live cell stain that fluoresces in the rhodamine channel so phalloidin that fluoresces in
the GFP channel had to be used on the LECs with the cancer gel co-culture. Whereas,
phalloidin that fluoresces in the rhodamine channel was used on the permeability
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studies.
Figure 27 shows the LECs from the cancer gel co-culture. Again, blue shows the
nucleus of the LECs and the green are the actin filaments. In these particular images,
the cells were seeded on 8 µm pore sized membranes. Even though the pore size is
quite large, the cells are still about 90% confluent. This pore size was chosen for
the cancer cells to be able to migrate through the membrane and endothelial layer.
Another important feature from these images is the even distribution of cells. This
is quite important, because inadequate cell densities can cause the LECs to start
differentiating, which would be highly undesirable.
Figure 27: LECs stained with dapi and phalloidin
Now, figure 28 shows an overlay of dapi, GFP, rhodamine, and the bright field
channel. In this case, dapi is again used to show the nucleus of the LECs, green
phalloidin shows the actin filaments, rhodamine shows the live cell dye of the cancer
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cells, and bright field shows the membrane. What is really interesting about these
images is the red tinge to the whole image. The camera was focused on the membrane
at the LEC layer, as shown by bright field and the LEC stains, but the cancer cells
can still be faintly seen in the background. The washed out appearance of the red
throughout the image indicates that the cancer cells are out of focus, as expected, but
also shows their presence. These images really highlight the potential for co-cultures
in this device as well as incite promising future experiments. For instance, if the
LECs could also have a live cell stain really interesting images could be taken during
static and flow experiments. You should be able to capture an image of a cancer cell
migrating through the LEC layer, as has been shown previously in fixed samples [37].
Figure 28: Co-culture of cancer cells with LECs
One challenge associated with fixing and staining the LECs is that the live cell
stain of the cancer cells severely diminishes upon fixation. This could be overcome by
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restaining the cancer cells and their nuclei with dapi and with a cell-specific antibody.
Figure 29 shows images of the LECs just stained with dapi and the cancer cells in
the background. At this point, 30 minutes had passed since the 4% PFA had been
introduced to the system. The difference in the intensity of the cancer cells between
these images and the previous figure are significant. Note, phalloidin takes an hour
so the images in figure 28 were taken at least an hour and half since the 4% PFA had
been introduced.
Figure 29: Co-culture with just dapi and rhodamine channels
Cancer cells can also be cultured independent of LECs as shown in figure 30. The
live cell stain does a good job at highlighting the cancer cells. These images also
show how evenly distributed the cancer cells are in the gel from side to side as well
as hinting at the distribution in the plane. Several cells can be seen just out of field.
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Figure 30: Bright field image of cancer cells with live cell dye
The final set of images are from the permeability studies, see figure 31. In these
images dapi and red phalloidin were used to again show the nucleus and actin fila-
ments. The cells are evenly distributed and about 85% confluent. Unfortunately, the
phalloidin stain is much harder to see than in the previous images. This is primarily
due to the integration time being too low. Unfortunately, the green phalloidin cannot
be used in this case due to the bodipy solution that is applied during the flow ex-
periments. The channels still fluoresce very intensely even once the bodipy has been
removed from the channel and the channel has been rinsed several times with PBS.
Figure 32 even shows bodipy deposits near the cells. Bodipy deposits are indicators
of lipid uptake. During the static and flow permeability studies, these deposits can be
seen in real time, meaning that bodipy is being taken up throughout the experiment.
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Figure 31: LECs stained with dapi and phalloidin
Figure 32: LECs stained with dapi and phalloidin with bodipy deposits
Overall, cells can be seeded on this device and kept alive while varying different
experimental conditions.
4.2 Aim 2: Permeability
If we recall from chapter 2, figure 5 shows a model that could be used for drug
screening, lipid uptake, or lymphedema studies. To establish that this model could be
used for studying lipid transport in any of these cases, permeability will be measured
in a static case and in a flow case, 0.175 mL/min (1/2 dyne/cm2). We are measuring
effective permeability because it quantifies the transport of a particular molecule
across a surface. In this case, fluorescently labeled dextran and bodipy will be used,
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because dextran is a standard molecule used for characterizing passive permeability






is influenced by flux, concentration, and surface area. Based on the designed system,
the exposed surface area of the membrane is constant at 0.5 mm2. This leaves flux
and concentration which are both conditional. Flux varies with the concentration
of the tracer and exposed volume over time, which means the value was significantly
higher in the flow case. For the flow case, flux is equal to the concentration multiplied
by the flow, 0.0029 mL/s (0.175 mL/min), as compared to the static case where flux
is equal to the concentration multiplied by the exposed volume over the time course,
6.4×10−6 mL/s (23 µL/hr). Just from these values we know that the flow case will
have a much higher effective permeability simply due to convection. This is because
the sink channel is being constantly diluted which means the concentration gradient
will larger than in the static case. Which further emphasizes how important flow is
to incorporate in lymphatic biology. It plays a huge role in inflammation and normal
fluid homeostasis and just from the effective permeability equation we can see how
important flux is on permeability.
The final value needed to find permeability is the concentration of the probe that
has been transported to the apical side of the lymphatics. Known concentration of
bodipy and dextran were put in the channel and images were taken of each. Then the
average intensity was found of that channel, see figure 33. Finally a standard curve,
see figure 34, was made for both bodipy and dextran by plotting concentration versus
average intensity.
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Figure 33: Region of interest used in channels
Figure 34: Intensity vs Concentration for bodipy (left) and dextran (right)
Concentrations of fluorescently labeled bodipy and dextran were added to the
bottom channel of the device, see figure 35. This channel corresponds to the no cell
and no flow channel. By putting the fluorescently labeled molecules in the no cell and
no flow channel the uptake into the lymphatics when vessel leaking is occurring could
be represented. If the solution was added to the cell and flow side instead, one could
quantify just vessel leakage. While both of these configurations have a purpose, the
uptake model was chosen simply because we know from chapter 2 that flow increases
the transport and uptake of lipids into lymphatics. Whereas, the other configuration
would just describe how leaky the system is.
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Figure 35: Flow model with optically labeled tracer in bottom channel
Once the average intensity of the channel show in figure 35 had been calculated
it was interpolated on to the previously mentioned standard curve to establish the
corresponding concentration. Finally, the difference in concentration from the initial
and final images was calculated.
Table 8 and figure 36 shows the progression of dextran in both the static and
flow cases. The image sequences show the initial image and then after 20, 35, and
50 minutes. For each of these cases, the effective permeability was calculated for
the duration of the experiment. In the static case, the average Peff=0.003 µm/s
and in the flow case Peff=0.126 µm/s. The static case permeability is less than the
value found by Dixon et al. in transwells, 0.065 µm/s [13]. The difference could be
due to different concentrations used. An important parameter to note is that flow
is recirculating in the sink channel of the flow case. So while it is not illuminating
as strongly as the static case, it is being spread over a much larger amount of fluid
and has a much larger fluid flux. This could be potentially problematic. While the
solution does eventually illuminate the time required to do so is much higher than in
the static case.
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Table 8: Flow increases effective permeability of Dextran





0 mins 20 mins 35 mins 50 mins
Figure 36: Dextran permeability throughout experiment for static (left) and flow
cases (right)
Table 9 and figure 37 also show the progression in the static and flow cases, but of
bodipy. What’s interesting in the bodipy case is the accumulation of bodipy deposits
in the cell layer. The deposits appear more frequently and in a higher quantity
for the flow case which corresponds to increase in lipid uptake when flow is present
[60]. These bodipy deposits appear as small dots in the sink channel and because
of this it is much easier to see the increased uptake of bodipy in the flow case. The
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calculated effective permeability is, as expected, much higher in the flow case. Where
the static case Peff=0.002 µm/s and in the flow case Peff=0.12 µm/s. The static
case permeability corresponds very closely with the value found by Dixon et al. of
0.005 µm/s [13]. These bodipy deposit regions can affect the permeability calculation
though, because the measured concentration of the solution will be be increased when
these deposits are available.
Table 9: Flow increases effective permeability of Bodipy





0 mins 20 mins 35 mins 50 mins
Figure 37: Bodipy permeability throughout experiment for static (left) and flow
cases (right)
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4.3 Aim 3: Migration
As mentioned in chapter 2, a model that shows migration through a tumor like
structure (collagen gel) into the lymphatics is useful for studying cancer cell homing
mechanisms to the lymphatics. In this model, see figure 6, cancer cells can be imaged
at multiple time intervals which allows for quantifying motility of cancer cells in the
collagen gel.
4.3.1 Interstitial Flow in Cancer Gel
Before delving into the quantification of migration, the interstitial flow rate through
the membrane of the cancer gel case needed to be calculated. This ensures that
biophysically relevant flows, 0.1 to 0.8 µm/s [52], are acting on the cancer cells. To
determine what the interstitial flow rate through the membrane, the flow rate entering
the gel channel was determined experimentally and then the input into a COMSOL
model.
Fluid was filled to the top of the tube holder column, see figure 38, and then after
12 hours the height of the fluid still in the column was measured. The fluid had
moved down half of the length of the tube column, 0.1 inches, and the diameter of
the column is 1/8 inch. Taking this displaced volume over the time and then dividing
by the channel cross-sectional area resulted in a velocity of 0.8 µm/s. Media was only
filled in one column to establish a hydrostatic pressure gradient to drive flow through
the cancer gel.
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Figure 38: Initial height of media added to channel (left) and final height after 12
hours (right)
A COMSOL model was created where the top channel was the cancer gel and
the bottom was just media. The properties for the media were set to the dynamic
viscosity and density of water at 37◦C. While the density of the collagen gel was set
to 9.3 mg/mL and the dynamic viscosity was 10 cP [33]. Figure 39 shows the side
view of the cross section and the isometric view of the channels. From figure 39 (left),
a range of 0 to 0.1 µm was set to distinguish the flow rate in the bottom channel
and we can see that the interstitial flow from the total velocity is around 0.1 µm/s
at the membrane interface, top of the colored rectangle, which is within the range for
acceptable interstitial flow.
Figure 39: Side view of cross-sectional area (left) and isometric view of model (right)
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4.3.2 Migration
ZR75-1 breast cancer cells were used in initial cancer migration studies, because they
were previously shown to have the strongest migratory response to flow and are known
to be highly metastatic [52]. The microscope was focused to a depth just above the
membrane in the collagen gel where cancer cells were present. This z slice depth
was used for all of the channels. Images were then taken every five minutes with the
rhodamine filter to capture the live cell dye on the cancer cells. This was done in
three channels, where one was static and the other two were with flow.
By only inducing flow through one column, flow through the gel occurs from left
to right as well as transmurally. To avoid this in the future both columns could be
filled with media to drive transmural flow.
Two different imaging techniques were used to quantify cancer cell migration
through this z slice. The first shows cell flux through this z slice and the second
shows cell motility.
4.3.2.1 Cell Flux
All collected images were binarized, thersholded to reduce noise, smoothed out with
a composite wavelet matched filter, and areas that were close to one another were
separated with a watershed technique to ensure any cells that were close to one
another were separated. Then a clustering technique was used to determine the
number of regions that were at least 100 square pixels. Where 100 square pixels is
about the minimum size of a cell. This clustering technique was used on the initial
image to establish the number of cells that were present to begin with. Then a
maximum intensity projection (MIP) was created by compressing all of the images
from the experiment into a single image that showed the presence of any cell that
had existed in the z slice throughout the experiment. The clustering technique was
used on the MIP to establish the number of cells that had ever been present in the
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z slice during the experiment. Table 10 shows the initial images and MIP images for
the static and two flow cases.
Table 10: Cell flux through collagen gel z slice
Static Flow 1 Flow 2
Initial
MIP




The static channel started with 79 cells and overall it had 94 cells present in that z
slice. Which indicates that at least 15 additional cells moved from the beginning of the
experiment to the end. Next, the first flow channel started with 64 cells and overall
it had 88 cells for an overall change of 24 cells. Last the second flow channel started
with 45 cells and overall it had 85 cells for a difference of 40 cells. While both the flow
channels had a larger difference in cells present, there is not enough evidence in this
model, yet, to establish a correlation between flow and cancer cell migration, but the
data suggests that the presence of flow increases cell migration which corresponds to
Shields et al. [52]. More experiments will need to be performed. This quantification
is useful for establishing the flux of cells through a z slice during a time course and it
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is a more accurate count of the number of cells present during the experiment than
the end-point count performed by Shields et al. though.
4.3.2.2 Cell Motility
As mentioned previously, a second technique was used to quantify cell motility. The
same images were used for both techniques, however, instead of counting the number
of regions that were large enough to be a cell the changes between time points was
calculated. To do this, each image had the previous image in the sequence subtracted
from it. For example, the fifth image captured would have the fourth image subtracted
from it. By doing this, the remaining image would show any changes that happened
to the cell locations between the time points in either depth or from side to side.
Figure 40 shows a subtracted image from the flow 1 channel. In this image two types
of movement can be seen. The first is the ring formed by changes in depth from
coming into and out of focus. While the second are crescents formed from side to side
movement.
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Figure 40: Resulting image from subtraction
The average intensity was taken of each of these subtracted images and plot versus
time, see figure 41. In this graph we see that static, flow 1 and flow 2 move at about
the same frequency which suggests cancer cells have the same motility regardless of
the presence of flow. The interesting trend is in the flow 2 case where the magnitude
and frequency of changes is relatively low in comparison to the other channels. Upon
inspection of the subtracted images, cells moved primarily in and out of focus in
this channel as opposed to moving from side to side. The intensity due to variations
in direction cannot be distinguished from the intensity due to the number of cells
present so directionality cannot be determine on its own. Also, the peaks happen
fairly regularly for the static and flow cases, this suggests that the flow case is just
as motile as the static case. What is most interesting question from this finding is, if
the cells are just as motile in the static case as the flow case then why do more cells
flux through the z slice as shown in the previous section? This further emphasizes the
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importance of including flow in migration models as it most likely is directing cancer
cell migration into the lymphatics.
Figure 41: Magnitude and frequency of movement changes
Overall, these two techniques may allow for quantification of cell flux as well as
show the motility of cells in this device. More experiments need to be performed,






With this device, I have shown that cells can be cultured on both membranes and
in collagen gels and are viable during experiments. I can induce both luminal and
transmural flow through this device and clear images of the channels can be taken.
I have demonstrated the possibility to calculate the effective permeability of two
fluorescently labeled transport molecules in both static and flow conditions. I have
presented potential quantification methods for measuring cell migration in real time
that shows both motility and flux of the cells which may be applied to further studying
cancer cell homing mechanisms into the lymphatics. Overall, this device addresses
all the designated aims in chapter 2, as well as sets the foundation for future studies
in both lipid transport and cancer cell migration.
5.1.1 Future Work
5.1.1.1 Lipid Transport
This device will be used to answer the following two questions.
How are lipid uptake mechanisms affected by transmural flow?
How is permeability affected by varying shear stress and by oscillatory luminal
flow?
The first will help in studying the fundamental mechanisms involved with lipid
uptake and could be beneficial in progress towards drug delivery through lymphatics.
The second would be useful for establishing how flow influences permeability and lipid
uptake due to changes in flow patterns as well as shear stress.
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5.1.1.2 Cancer Metastasis
For the cancer model, there are also two questions of interest.
How does the presence of lipoproteins affect cancer cell migration?
How is cancer cell migration affected by luminal flow across the LEC layer?
Hyperlipidemia patients have been shown to have favorable circumstance for can-
cer growth [31] so the main point of the first question is to see if these additional
lipoproteins influence cancer cell migration in any way. The migration quantification
methods shown in this thesis will prove to be very useful for answering this question.
The second, as shown in figure 42, luminal flow would be induced across a LEC layer
which should increase the CCL19/21 concentration gradient and cause an even more
profound migration of cancer cells to the LECs. Where the pressure gradient through
the membrane formed by the flow through the collagen gel would be greater than the
pressure gradient through the membrane caused by the luminal flow.











files = dir('Background/Dextran/*.TIF');    %Finds all tif files in folder
num_files = numel(files);                   %Finds number of images
Look = dir('Background/Dextran/*.jpg');     %Finds jpg
a=imread(Look(1).name);                     %Reads image
mask=roipoly(a);                            %Create ROI mask
close                                       %Close window
for k = 1:num_files                         %Loop through all images
    a=imread(files(k).name);                %Read in image
    b(k)=mean2(a(mask));                    %Average intensity of mask on 
each image
end
c1=mean(b);                                 %Average over set
 
%Dextran 001
files = dir('001/Dextran/*.TIF');           %Finds all tif files in folder
num_files = numel(files);                   %Finds number of images
for k = 1:num_files                         %Loop through all images
    a=imread(files(k).name);                %Read in image
    b(k)=mean2(a(mask));                    %Average intensity of mask on 
each image
end
Ed1=std(b);                                 %Standard Deviation
cD1=mean(b-c1);                             %Average over set
 
%Dextran 003
files = dir('003/Dextran/*.TIF');           %Finds all tif files in folder
num_files = numel(files);                   %Finds number of images
for k = 1:num_files                         %Loop through all images
    a=imread(files(k).name);                %Read in image
    b(k)=mean2(a(mask));                    %Average intensity of mask on 
each image
end
Ed3=std(b);                                 %Standard Deviation
cD3=abs(mean(b-c1));                        %Average over set
 
%Dextran 005
files = dir('005/Dextran/*.TIF');           %Finds all tif files in folder
num_files = numel(files);                   %Finds number of images
for k = 1:num_files                         %Loop through all images
    a=imread(files(k).name);                %Read in image
    b(k)=mean2(a(mask));                    %Average intensity of mask on 
each image
end
Ed5=std(b);                                 %Standard Deviation
cD5=mean(b-c1);                             %Average over set
 
%Dextran 007
files = dir('007/Dextran/*.TIF');           %Finds all tif files in folder
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num_files = numel(files);                   %Finds number of images
for k = 1:num_files                         %Loop through all images
    a=imread(files(k).name);                %Read in image
    b(k)=mean2(a(mask));                    %Average intensity of mask on 
each image
end
Ed7=std(b);                                 %Standard Deviation
cD7=mean(b-c1);                             %Average over set
 
%Dextran 009
files = dir('009/Dextran/*.TIF');           %Finds all tif files in folder
num_files = numel(files);                   %Finds number of images
for k = 1:num_files                         %Loop through all images
    a=imread(files(k).name);                %Read in image
    b(k)=mean2(a(mask));                    %Average intensity of mask on 
each image
end
Ed9=std(b);                                 %Standard Deviation
cD9=mean(b-c1);                             %Average over set
 
%Dextran 02
files = dir('02/Dextran/*.TIF');            %Finds all tif files in folder
num_files = numel(files);                   %Finds number of images
for k = 1:num_files                         %Loop through all images
    a=imread(files(k).name);                %Read in image
    b(k)=mean2(a(mask));                    %Average intensity of mask on 
each image
end
Ed20=std(b);                                %Standard Deviation
cD20=mean(b-c1);                            %Average over set
 
%Dextran 04
files = dir('04/Dextran/*.TIF');            %Finds all tif files in folder
num_files = numel(files);                   %Finds number of images
for k = 1:num_files                         %Loop through all images
    a=imread(files(k).name);                %Read in image
    b(k)=mean2(a(mask));                    %Average intensity of mask on 
each image
end
Ed40=std(b);                                %Standard Deviation
cD40=mean(b-c1);                            %Average over set
 
%Dextran 06
files = dir('06/Dextran/*.TIF');            %Finds all tif files in folder
num_files = numel(files);                   %Finds number of images
for k = 1:num_files                         %Loop through all images
    a=imread(files(k).name);                %Read in image
    b(k)=mean2(a(mask));                    %Average intensity of mask on 
each image
end
Ed60=std(b);                                %Standard Deviation




files = dir('08/Dextran/*.TIF');            %Finds all tif files in folder
num_files = numel(files);                   %Finds number of images
for k = 1:num_files                         %Loop through all images
    a=imread(files(k).name);                %Read in image
    b(k)=mean2(a(mask));                    %Average intensity of mask on 
each image
end
Ed80=std(b);                                %Standard Deviation
cD80=mean(b-c1);                            %Average over set
 
%Dextran 1
files = dir('1/Dextran/*.TIF');             %Finds all tif files in folder
num_files = numel(files);                   %Finds number of images
for k = 1:num_files                         %Loop through all images
    a=imread(files(k).name);                %Read in image
    b(k)=mean2(a(mask));                    %Average intensity of mask on 
each image
end
Ed100=std(b);                               %Standard Deviation
cD100=mean(b-c1);                           %Average over set
 
%Background Bodipy
files = dir('Background/Bodipy/*.TIF');     %Finds all tif files in folder
num_files = numel(files);                   %Finds number of images
Look2 = dir('Background/Bodipy/*.jpg');     %Finds jpg
a=imread(Look2(1).name);                    %Reads image
mask=roipoly(a);                            %Create ROI mask
close                                       %Close window
for k = 1:num_files                         %Loop through all images
    a=imread(files(k).name);                %Read in image
    b(k)=mean2(a(mask));                    %Average intensity of mask on 
each image
end
c2=mean(b);                                 %Average over set
 
%Bodipy 001
files = dir('001/Bodipy/*.TIF');            %Finds all tif files in folder
num_files = numel(files);                   %Finds number of images
for k = 1:num_files                         %Loop through all images
    a=imread(files(k).name);                %Read in image
    b(k)=mean2(a(mask));                    %Average intensity of mask on 
each image
end
Eb1=std(b);                                 %Standard Deviation
cB1=mean(b-c2);                             %Average over set
 
%Bodipy 003
files = dir('003/Bodipy/*.TIF');            %Finds all tif files in folder
num_files = numel(files);                   %Finds number of images
for k = 1:num_files                         %Loop through all images
    a=imread(files(k).name);                %Read in image




Eb3=std(b);                                 %Standard Deviation
cB3=mean(b-c2);                             %Average over set
 
%Bodipy 005
files = dir('005/Bodipy/*.TIF');            %Finds all tif files in folder
num_files = numel(files);                   %Finds number of images
for k = 1:num_files                         %Loop through all images
    a=imread(files(k).name);                %Read in image
    b(k)=mean2(a(mask));                    %Average intensity of mask on 
each image
end
Eb5=std(b);                                 %Standard Deviation
cB5=mean(b-c2);                             %Average over set
 
%Bodipy 007
files = dir('007/Bodipy/*.TIF');            %Finds all tif files in folder
num_files = numel(files);                   %Finds number of images
for k = 1:num_files                         %Loop through all images
    a=imread(files(k).name);                %Read in image
    b(k)=mean2(a(mask));                    %Average intensity of mask on 
each image
end
Eb7=std(b);                                 %Standard Deviation
cB7=mean(b-c2);                             %Average over set
 
%Bodipy 009
files = dir('009/Bodipy/*.TIF');            %Finds all tif files in folder
num_files = numel(files);                   %Finds number of images
for k = 1:num_files                         %Loop through all images
    a=imread(files(k).name);                %Read in image
    b(k)=mean2(a(mask));                    %Average intensity of mask on 
each image
end
Eb9=std(b);                                 %Standard Deviation
cB9=mean(b-c2);                             %Average over set
 
%Bodipy 02
files = dir('02/Bodipy/*.TIF');             %Finds all tif files in folder
num_files = numel(files);                   %Finds number of images
for k = 1:num_files                         %Loop through all images
    a=imread(files(k).name);                %Read in image
    b(k)=mean2(a(mask));                    %Average intensity of mask on 
each image
end
Eb20=std(b);                                %Standard Deviation
cB20=mean(b-c2);                            %Average over set
 
%Bodipy 04
files = dir('04/Bodipy/*.TIF');             %Finds all tif files in folder
num_files = numel(files);                   %Finds number of images
for k = 1:num_files                         %Loop through all images
    a=imread(files(k).name);                %Read in image




Eb40=std(b);                                %Standard Deviation
cB40=mean(b-c2);                            %Average over set
 
%Bodipy 06
files = dir('06/Bodipy/*.TIF');             %Finds all tif files in folder
num_files = numel(files);                   %Finds number of images
for k = 1:num_files                         %Loop through all images
    a=imread(files(k).name);                %Read in image
    b(k)=mean2(a(mask));                    %Average intensity of mask on 
each image
end
Eb60=std(b);                                %Standard Deviation
cB60=mean(b-c2);                            %Average over set
 
%Bodipy 08
files = dir('08/Bodipy/*.TIF');             %Finds all tif files in folder
num_files = numel(files);                   %Finds number of images
for k = 1:num_files                         %Loop through all images
    a=imread(files(k).name);                %Read in image
    b(k)=mean2(a(mask));                    %Average intensity of mask on 
each image
end
Eb80=std(b);                                %Standard Deviation
cB80=mean(b-c2);                            %Average over set
 
%Bodipy 1
files = dir('1/Bodipy/*.TIF');              %Finds all tif files in folder
num_files = numel(files);                   %Finds number of images
for k = 1:num_files                         %Loop through all images
    a=imread(files(k).name);                %Read in image
    b(k)=mean2(a(mask));                    %Average intensity of mask on 
each image
end
Eb100=std(b);                               %Standard Deviation





conc=[0.001, 0.003, 0.005, 0.007, 0.009, 0.02, 0.04 0.06, 0.08, 0.1];   
%Concentration values
 
Ed=[Ed1,Ed3,Ed5,Ed7,Ed9,Ed20,Ed40,Ed60,Ed80,Ed100]; %Standard Deviations 
Dextran
Eb=[Eb1,Eb3,Eb5,Eb7,Eb9,Eb20,Eb40,Eb60,Eb80,Eb100]; %Standard Deviations 
Bodipy
 
















cB=[0 61.8 149.9 286.9 368 478.9 1132.2 2078.8 2978.1 3705.3 4224.1];         
%Bodipy Values from Intensity
cD=[4.9507 3.7891 3.3300 5.7697 7.7725 16.4812 39.0864 63.4297 91.5546 
111.6085];   %Dextran Values from Intensity
conc=[0.001, 0.003, 0.005, 0.007, 0.009, 0.02, 0.04 0.06, 0.08, 0.1];         
%Concentration values





files = dir('Flow Transport/Channel 1/Bodipy/Jpeg/*.jpg');  %Finds all tif 
files in folder
num_files = numel(files);                                   %Finds number of 
images
t1=(0:300:300*(num_files-1))/3600;                          %Time between 
each image
a=imread(files(1).name);                                    %Read in image
mask1=roipoly(a);                                           %Create ROI mask
mask2=roipoly(a);
mask3=roipoly(a);
close                                                       %Close window
for k = 1:num_files                                         %Loop through all 
images
    a=imread(files(k).name);                                %Read in image
    bF1(k)=mean2(a(mask1));                                 %Average 
intensity of mask on image
    bF2(k)=mean2(a(mask2));
    bF3(k)=mean2(a(mask3));
    q1_1(k)=interp1(cB,concB,bF1(k));    %Concentraion
    q1_2(k)=interp1(cB,concB,bF2(k));
    q1_3(k)=interp1(cB,concB,bF3(k));
    J_bF1(k)=q1_1(k)*0.0029;                    %Flux
    J_bF2(k)=q1_2(k)*0.0029;




files = dir('Flow Transport/Channel 1/Dextran/Jpeg/*.jpg');  %Finds all tif 
files in folder
num_files = numel(files);                                   %Finds number of 
images
a=imread(files(1).name);                                    %Read in image




close                                                       %Close window
for k = 1:num_files                                         %Loop through all 
images
    a=imread(files(k).name);                                %Read in image
    dF1(k)=mean2(a(mask1));                                 %Average 
intensity of mask on image
    dF2(k)=mean2(a(mask2));
    dF3(k)=mean2(a(mask3));
    q2_1(k)=interp1(cD,conc,dF1(k));     %Concentraion
    q2_2(k)=interp1(cD,conc,dF2(k));
    q2_3(k)=interp1(cD,conc,dF3(k));
    J_dF1(k)=q2_1(k)*0.0029;                 %Flux
    J_dF2(k)=q2_2(k)*0.0029;





files = dir('101211/Bodipy/*.jpg');  %Finds all tif files in folder
num_files2 = numel(files);                                   %Finds number of 
images
t2=(0:300:300*(num_files2-1))/3600;                          %Time between 
each image
a=imread(files(1).name);                                    %Read in image
mask1=roipoly(a);                                           %Create ROI mask
mask2=roipoly(a);
mask3=roipoly(a);
close                                                       %Close window
k=1;
for k = 1:num_files2                                         %Loop through 
all images
    a=imread(files(k).name);                                %Read in image
    bS1(k)=mean2(a(mask1));                                 %Average 
intensity of mask on image
    bS2(k)=mean2(a(mask2));
    bS3(k)=mean2(a(mask3));
    q3_1(k)=interp1(cB,concB,bS1(k)); %Concentraion
    q3_2(k)=interp1(cB,concB,bS2(k));
    q3_3(k)=interp1(cB,concB,bS3(k));
    J_bS1(k)=q3_1(k)*0.023/(max(t2)*3600);                 %Flux
    J_bS2(k)=q3_2(k)*0.023/(max(t2)*3600);




files = dir('101211/Dextran/*.jpg');  %Finds all tif files in folder
num_files2 = numel(files);                                   %Finds number of 
images
a=imread(files(1).name);                                    %Read in image
mask1=roipoly(a);                                           %Create ROI mask
mask2=roipoly(a);
mask3=roipoly(a);
close                                                       %Close window
for k = 1:num_files2                                         %Loop through 
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all images
    a=imread(files(k).name);                                %Read in image
    dS1(k)=mean2(a(mask1));                                 %Average 
intensity of mask on image
    dS2(k)=mean2(a(mask2));
    dS3(k)=mean2(a(mask3));
    q4_1(k)=interp1(cD,conc,dS1(k)); %Concentraion
    q4_2(k)=interp1(cD,conc,dS2(k));
    q4_3(k)=interp1(cD,conc,dS3(k));
    J_dS1(k)=q4_1(k)*0.023/(max(t2)*3600);                 %Flux
    J_dS2(k)=q4_2(k)*0.023/(max(t2)*3600);









for m = 2:num_files
    P_bF1(m)=J_bF1(m)/((q1_1(m)-q1_1(n))*S);  
    P_bF2(m)=J_bF2(m)/((q1_2(m)-q1_2(n))*S);  
    P_bF3(m)=J_bF3(m)/((q1_3(m)-q1_3(n))*S);  
    P_bFstd=[P_bF1(m) P_bF2(m) P_bF3(m)];
    P_bF(m)=(P_bF1(m)+P_bF2(m)+P_bF3(m))/3;
    EbF(m)=std(P_bFstd);
    P_dF1(m)=J_dF1(m)/((q2_1(m)-q2_1(n))*S);  
    P_dF2(m)=J_dF2(m)/((q2_2(m)-q2_2(n))*S);  
    P_dF3(m)=J_dF3(m)/((q2_3(m)-q2_3(n))*S);  
    P_dFstd=[P_dF1(m) P_dF2(m) P_dF3(m)];
    P_dF(m)=(P_dF1(m)+P_dF2(m)+P_dF3(m))/3;
    EdF(m)=std(P_dFstd);
    n=m;
end
n=1;
for m = 2:num_files2
    P_bS1(m)=J_bS1(m)/((q3_1(m)-q3_1(n))*S);  
    P_bS2(m)=J_bS2(m)/((q3_2(m)-q3_2(n))*S);  
    P_bS3(m)=J_bS3(m)/((q3_3(m)-q3_3(n))*S);  
    P_bSstd=[P_bS1(m) P_bS2(m) P_bS3(m)];
    P_bS(m)=(P_bS1(m)+P_bS2(m)+P_bS3(m))/3;
    EbS(m)=std(P_bSstd);
    P_dS1(m)=J_dS1(m)/((q4_1(m)-q4_1(n))*S);  
    P_dS2(m)=J_dS2(m)/((q4_2(m)-q4_2(n))*S);  
    P_dS3(m)=J_dS3(m)/((q4_3(m)-q4_3(n))*S);  
    P_dSstd=[P_dS1(m) P_dS2(m) P_dS3(m)];
    P_dS(m)=(P_dS1(m)+P_dS2(m)+P_dS3(m))/3;
    EdS(m)=std(P_dSstd);























files = dir('channel1/Channel 1/*.tiff');   %Finds all tif files in folder
num_files = numel(files);                   %Finds number of images
t1=(0:300:300*(num_files-1))/3600;          %Time between each image
j=1;                                        %Set counter to 1
for k = 1:num_files                         %Loop that goes through all 
images
    a=imread(files(k).name);                %Reads current image
    b=imread(files(j).name);                %Reads previous image
    c=a-b;                                  %Difference in images
    D1(k) = mean2(c);                       %Find average intensity in 
subtracted image




files3 = dir('channel3/Channel 3/*.tiff');  %Finds all tif files in folder
num_files3 = numel(files3);                 %Finds number of images
t3=(0:300:300*(num_files3-1))/3600;         %Time between each image
l=1;                                        %Set counter to 1
for m = 1:num_files3                        %Loop that goes through all 
images
    a3=imread(files3(m).name);              %Reads current image
    b3=imread(files3(l).name);              %Reads previous image
    c3=a3-b3;                               %Difference in images
    D3(m) = mean2(c3);                      %Find average intensity in 
subtracted image




files4 = dir('channel4/Channel 4/*.tiff');  %Finds all tif files in folder
num_files4 = numel(files4);                 %Finds number of images
t4=(0:300:300*(num_files4-1))/3600;         %Time between each image
n=1;                                        %Set counter to 1
for o = 1:num_files4                        %Loop that goes through all 
images
    a4=imread(files4(o).name);              %Reads current image
    b4=imread(files4(n).name);              %Reads previous image
    c4=a4-b4;                               %Difference in images
    D4(o) = mean2(c4);                      %Find average intensity in 
subtracted image






title('Intensity Magnitude of Cell Location Changes')
xlabel('Time (hour)')
ylabel('Average Intensity')




Figure 43: Boundary conditions
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Figure 44: Subdomain conditions
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